AMENDMENTS TO THE CLAIMS

1. (Withdrawn) Pharmaceutical composition characterized by containing Silymarin and Carbopol and a pharmaceutically acceptable vehicle.

2. (Withdrawn) Composition in accordance with claim 1 characterized by containing 3 to 7% Silymarin and 0.2 to 0.6% Carbopol.

3. (Withdrawn) Composition in accordance with claim 2 where it preferably contains 5% Silymarin and 0.5% Carbopol.

4. (Withdrawn) Composition in accordance with claims 1 to 3 where the pharmaceutical composition may be in the form of an oral dose.

5. (Withdrawn) Composition in accordance with claim 4 where the oral form may be a suspension, oral solution, emulsion, gel, hard gelatin capsule, soft gelatin capsule, immediate release tablet, controlled release tablet, prolonged release or sustained release tablet.

6. (Withdrawn) Composition in accordance with claim 5 where it is preferably in the form of an oral suspension.

7. – 9. Cancelled.

10. (Withdrawn) Procedure for obtaining the composition of claims 1 to 3 consisting of the following steps:

a)Dissolution of 0.2 to 0.6% of Carbopol in deionized water, subjecting it to agitation for a period of time of 50 to 90 minutes.

b)Addition of Silymarin in a percentage of 3 to 7 to the foregoing dissolution and subjected to agitation for a minimum period of one hour until a homogenous mixture is obtained.

11. (Withdrawn) Procedure in accordance with claim 9 where preferably 0.5% of Carbopol and 5% of Silymarin are dissolved.

12. (Withdrawn) Process in accordance with claim 9 where it optionally has a subsequent step of solubilization.

13. (Withdrawn) Process in accordance with claim 9 where it optionally has a subsequent step of emulsification.

14. (Withdrawn) Process in accordance with claim 9 where it optionally has a subsequent step of gelation.

15. (Withdrawn) Process in accordance with claim 9 where it optionally has a subsequent step of encapsulation.

16. (Withdrawn) Process in accordance with claim 9 where it optionally has a subsequent tablet-making step.

17. – 26. (Cancelled)

27. (New) A method of recovering endocrine pancreatic function in a patent in need thereof, which comprises

orally administering to the patient an effective amount of a composition comprising Silymarin and Carbopol, capable of regenerating damaged pancreatic cells.

28. (New) The method for recovering endocrine pancreatic function according to claim 27, which comprises

administering to the patient a composition comprising 3 to 7% Silymarin and 0.2 to 0.6% Carbopol.

29. (New) The method for recovering endocrine pancreatic function according to claim 28, wherein the composition comprises 5.0% Silymarin and 0.5% Carbopol.

30. (New) The method for recovering endocrine pancreatic function according to any of claims 27 through 29, wherein the oral form is a suspension, an oral solution, an emulsion, gel, a hard gelatin capsule, a soft gelatin capsule, an immediate release tablet, a controlled release tablet, a prolonged release or a sustained release tablet.